10 unknown, 9 recruiting, 4 not yet recruiting, 1 completed. 16 Phase 2, 9 Phase 1, 4 Not applicable, 2 Phase 3.
Follow Mitoxantrone Hydrochloride Liposome: new trials by email Literature Review of Mitoxantrone Hydrochloride Liposome trials Research Report on Mitoxantrone Hydrochloride Liposome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML Mitoxantrone Hydrochloride Liposome, Cytarabine, Granulocyte Colony-Stimulating Factor(G-CSF) - Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) | Phase 3 | Not yet recruiting | Ruijin Hospital | 168 | 2026-07-30 | 2026-07-29 |
| Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML Mitoxantrone Hydrochloride Liposome, Venetoclax, Azacitidine - Acute Myeloid Leukemia (AML) | Phase 3 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 204 | 2026-03-10 | 2026-03-20 |
| Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL Zeprumetostat, Azacitidine (AZA), Mitoxantrone Hydrochloride Liposome - Peripheral T Cells Lymphoma (PTCL) | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 26 | 2026-01-15 | 2026-01-28 |
| Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma Golidocitinib, Mitoxantrone Hydrochloride Liposome, Chidamide - Peripheral T Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Sun Yat-sen University | 101 | 2025-08-27 | 2025-12-31 |
| Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial Ivonescimab, Nimotuzumab, Irinotecan liposome - Recurrent or Metastatic Nasopharyngeal Carcinoma | Phase 2 | Recruiting | Ming-Yuan Chen | 208 | 2025-06-24 | 2025-09-18 |
| JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer Mitoxantrone Hydrochloride Liposome, JMT101 injection, Capecitabine - Recurrent or Metastatic Nasopharyngeal Cancer, Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy | Phase 2 | Not yet recruiting | Shanghai JMT-Bio Inc. | 150 | 2025-04-01 | 2025-03-25 |
| Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML Mitoxantrone hydrochloride liposome, Cytarabine, Venetoclax - Acute Myeloid Leukemia | Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | 42 | 2024-07-08 | 2024-10-01 |
| Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML mitoxantrone hydrochloride liposome, Cytarabine, Venetoclax - Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy | Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | 72 | 2024-07-05 | 2025-09-16 |
| R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma Mitoxantrone Hydrochloride Liposome, Rituximab (R), Cyclophosphamide (CTX) - Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 108 | 2024-05-30 | 2026-06-10 |
| Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL Linperlisib, Rituximab, Gemcitabine - Relapsed/Refractory Large B-Cell Lymphoma | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 89 | 2024-05-28 | 2024-07-08 |
| Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML MTBF regimen - Relapse Leukemia, Refractory Acute Myeloid Leukemia | Not applicable | Not yet recruiting | First Affiliated Hospital Xi'an Jiaotong University | 37 | 2024-05-01 | 2024-04-26 |
| VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT Mitoxantrone hydrochloride liposome - Relapse Acute Myeloid Leukemia | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 30 | 2024-04-12 | 2024-06-06 |
| Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML mitoxantrone hydrochloride liposome, Cytarabine, Venetoclax - Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy | Phase 2 | Unknown | First Affiliated Hospital of Zhejiang University | 34 | 2024-02-29 | 2024-05-30 |
| Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML Homoharringtonine, Cytarabine, Etoposide - AML, Childhood, Acute Myeloid Leukemia | Phase 2 | Recruiting | Children's Hospital of Soochow University | 500 | 2024-01-01 | 2024-08-22 |
| Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer Mitoxantrone hydrochloride liposome, Capecitabine - Breast Cancer | Not applicable | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 24 | 2023-11-28 | 2023-12-05 |
| Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma Mitoxantrone hydrochloride liposome/Dexamethasone/daratumumab - Relapsed/Refractory Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Second Affiliated Hospital of Soochow University | 20 | 2023-05-20 | 2023-05-15 |
| R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Rituximab, Mitoxantrone hydrochloride liposome, Isophosphamide - Diffuse Large B-cell Lymphoma | Not applicable | Unknown | The First Affiliated Hospital with Nanjing Medical University | 60 | 2023-04-15 | 2023-03-27 |
| R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma Rituximab, Mitoxantrone hydrochloride liposome, Cyclophosphamide - Diffuse Large B-cell Lymphoma | Not applicable | Unknown | The First Affiliated Hospital with Nanjing Medical University | 30 | 2023-03-01 | 2023-03-21 |
| Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors Mitoxantrone Hydrochloride Liposome, Irinotecan, Vincristine - Pediatric Solid Tumor | Phase 1 | Unknown | Sun Yat-sen University | 68 | 2022-10-25 | 2024-07-09 |
| Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma Mitoxantrone Hydrochloride Liposome, Rituximab, Lenalidomide - Diffuse Large B-cell Lymphoma | Phase 2 | Unknown | Jianfeng Zhou | 55 | 2022-10-10 | 2022-10-12 |
Showing 20 of 26. Sign in to see all of them.
Leukemia, Myeloid, Acute (8) · Recurrence (6) · Lymphoma, Large B-Cell, Diffuse (4) · Multiple Myeloma (2) · Breast Neoplasms (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell, Peripheral (1) · Myelodysplastic Syndromes (1) · Nasopharyngeal Carcinoma (1) · Nasopharyngeal Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (5) · First Affiliated Hospital of Zhejiang University (3) · Institute of Hematology & Blood Diseases Hospital, China (3) · Sun Yat-sen University (2) · The First Affiliated Hospital of Soochow University (2) · The First Affiliated Hospital with Nanjing Medical University (2) · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Children's Hospital of Soochow University (1) · First Affiliated Hospital Xi'an Jiaotong University (1) · Jianfeng Zhou (1) · Ming-Yuan Chen (1) · Ruijin Hospital (1) · Second Affiliated Hospital of Soochow University (1) · Shanghai JMT-Bio Inc. (1)
China (19) · United States (1)
Wei Xu, PhD& MD (2) · Yuankai Shi, Ph.D (2) · Binghe Xu, PHD (1) · Bingzong LI (1) · Depei Wu (1) · Jianliang Yang, Ph.D (1) · Jie Jin, M.D. (1) · Lugui Qiu (1) · Lugui Qiu, Professor (1) · Nashat Y Gabrail, M.D. (1) · Shaoyan Hu, MD, PhD (1) · Sujiang Zhang (1) · Wenming Chen (1) · Xiaohong Han, Ph.D (1) · Xiaoning Wang, M.D. (1)